Aprogen Medicines Inc. reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported sales was KRW 39,857.79 million compared to KRW 27,680.66 million a year ago. Net loss was KRW 33,381.38 million compared to KRW 16,652.18 million a year ago. Basic loss per share from continuing operations was KRW 142 compared to KRW 74 a year ago. Diluted loss per share from continuing operations was KRW 142 compared to KRW 74 a year ago. Basic loss per share was KRW 142 compared to KRW 74 a year ago.
For the nine months, sales was KRW 1,328.52 million compared to KRW 1,018.61 million a year ago. Net loss was KRW 72,936.37 million compared to KRW 74,663.72 million a year ago. Basic loss per share from continuing operations was KRW 312 compared to KRW 392 a year ago. Diluted loss per share from continuing operations was KRW 312 compared to KRW 392 a year ago. Basic loss per share was KRW 312 compared to KRW 392 a year ago.